Novel therapies for high-grade gliomas: A vision for future

Autor: G Kohanbash, C Belka, RE Coleman, D Barba, JH Kim, H Burris, E Razis, C Sturiale, Lesniak, SA Grossman, B Dhokia, MP Gustafson, ZQ Han, P Traxler, AM Sandmair, LM DeAngelis, G Franceschi, P Msaouel, G Kaur, MJ Zhu, S Taillibert, I Yang, M Brown, AT Bruce, HP Kalofonos, T Todo, TC Liu, HS Hochster, KL Black, C Royce, D Fukumura, NL Spector, P Duic, MP Sayers, M Koslow, C Stanton, KL Fink, L Kim, JM Reid, AK Muhammad, JS Yu, AH Friedman, T Gohongi, KA Kreuzer, R Cozens, GP Dunn, DA Haas-Kogan, KB Hymes, JH Sampson, DD Song, RB Herberman, R Ramina, K Kawakami, GG Gomez, N Jelluma, E Galanis, SC Saris, S Thomas, Sy Lim, FM Iwamoto, AJ Grant, H Bender, W Xia, C Wallace, LH Merchant, S Kunwar, RD Schreiber, RE Merchant, AM Kaplan, Vivek Tandon, JS Hardwick, K Ballman, Berger, I Stroud, D Fabbro, JM Piepmeier, WK Yung, JC Hiserodt, K Moore, YB Wang, L Zhang, R Alemany, N Dmitrieva, HJ Choi, KM Kroeger, CD Stiles, D Schiff, LJ Old, JL Clarke, AL Asher, DV Woo, JL Mahaley, R Brandt, P Clement, JI Kreisberg, M Ehtesham, FK Miura, EM Hiesiger, I Cokgor, PY Wen, IK Na, C Crane, LB Nabors, HI Robins, HT Chung, G Ibrahim, NK Kim, A Arista, K Panageas, S Ahmad, RK Jain, KL Penne, JJ Vredenburgh, GD King, M Weller, CT Kuan, T Tihan, H Wakimoto, R Sakalas, CW Reynolds, JC Buckner, S Lassiter, HF Young, M Kioi, H Fukuhara, J Wykosky, MA Vogelbaum, TN Kreisl, H Okada, RE McLendon, V Jendrossek, CJ Wikstrand, P Puranen, M Puranen, W Xiong, Mahaley, YY Kim, C Sauvageot, JA Quinn, SR Husain, S Labropoulos, IF Pollack, CH Tung, J Laterra, JM Dowell, HS Friedman, A Desjardins, EC Dees, K Shah, BK Cho, C Valiengo Lda, GC Gonzalez, P Forsyth, M Assenberg, W Debinski, P Riva, JC Rodrigues, DA Eberhard, S Xia, SM Chang, Jy Yoo, J Hardcastle, CA Kruse, TJ Liu, R Weissleder, Jr MahaleyMS, D Snook, W Roth, Subhashree Mahapatra, M Frattarelli, KC Wang, FF Lang, KA Jaeckle, EA Chiocca, K Terada, C Gomez-Manzano, PR Lowenstein, JJ Kelly, SA Rosenberg, P Selviaridis, Prados, IV Ulasov, E Tyminski, S Sinha, RL Hayes, J Brueggen, T Kuroda, GJ Baker, J Sul, G Simpson, M Rackover, SK Kim, DD Bigner, S Desideri, K Hopkins, XO Breakefield, JN Rich, H Ikeda, M Kawakami, JM Bruner, M Rosenfeld, ND Arvold, PH Aguiar, LW Brady, D Morris, G Roldan, M Candolfi, S Kesari, B Seed, BH Joshi, M Holdhoff, RL Martuza, YG Kwon, SX Jiang, JT Kemshead, M Campone, NL Vujanovic, Y Chen, DA Reardon, TF Cloughesy, A Dispenzieri, M van den Bent, M Kossila, B Hildebrandt, EH Oldfield, S Puri, T Zhang, K Kurozumi, S Loimas, MK Wibowo, C Holder, EM Rosen, H Hurwitz, G Dresemann, EC Kim, H Assi, BL Liu, N Butowski, C Appelt, Groves, EJ Moore, SJ Han, CA Palmer, N Ramakrishna, J Emrich, MJ Maurer, RK Puri, JL Norris, P Waterman, J Clarke, S Piantadosi, T Peery, JF Curtin, LE Abrey, AS Chi, N Courtenay-Luck, A Hemingway, Y Saeki, AB Lassman, V Papanastassiou, J Boni, ED Day, E Hussain, C Miyamoto, AK Mahapatra, R Scholz, AT Parsa, RB Greeno, KL Low, T Mikkelsen, S Chang, C Sarkar, J Fueyo, DV Cramer, PR Allegrini, A Dowlati, DM Gibo, L Xu, M Dey, MM Ames, M Shaffrey, HA McDonald, SB Omay, TR Pawlikowska, RL Hamilton, D George, N Riva, Ashok Kumar Mahapatra, A Immonen, TA Mattei, M Bamberg, X Ye, B Woodhall

Publikováno v: Indian Journal of Neurosurgery, Vol 01, Iss 01, Pp 054-060 (2012)

The treatment for high-grade glioma remains an enigma. The standard treatment using surgery, radiation therapy and chemotherapy for such highly malignant lesions has only yielded modest results, in terms of survival and improving the quality of life

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::831d1b23c52c18a1f1c51646572e45e9
http://www.thieme-connect.de/DOI/DOI?10.4103/2277-9167.94372

Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer

Autor: Hi, Robins, Am, Traynor, minesh mehta

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4499d9e1c13641925fd777d2b5e0b5a9
https://pubmed.ncbi.nlm.nih.gov/17409864

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report

Autor: Sm, Chang, Jg, Kuhn, Hi, Robins, Sc, Schold, Am, Spence, Ms, Berger, minesh mehta, Me, Bozik, Pollack I, Schiff D, Gilbert M, Rankin C, Md, Prados

Publikováno v: Europe PubMed Central

PURPOSE: To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent. PATIENTS A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a5dfb914c185a767e954614472541b7
http://europepmc.org/abstract/med/10071293

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825.

Autor: Strauss JD; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX., Gilbert MR; National Institutes of Health, Bethesda, MD., Mehta M; Miami Cancer Institute, Miami, FL., Li A; Baylor College of Medicine, Houston, TX., Ms RZ; Zai Lab (US) LLC, Menlo Park, CA., Bondy ML; Stanford University, Stanford, CA., Sulman EP; Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, NY., Yuan Y; M D Anderson Cancer Center, Houston, TX., Liu Y; Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX., Vera E; National Institutes of Health, Bethesda, MD., Wendland MM; Willamette Valley Cancer Center, Eugene, OR., Stieber VW; Novant Health Forsyth Medical Center, Winston-Salem, NC., Puduvalli VK; M D Anderson Cancer Center, Houston, TX., Choi S; Mary Hillman Jennings Radiation Oncology Center, Pittsburgh, PA., Martinez NL; Thomas Jefferson University Hospital, Philadelphia, PA., Robins HI; University of Wisconsin Carbone Cancer Center, Madison, WI., Hunter GK; Intermountain Medical Center, Wilkes-Barre Township, PA., Lin CF; Baylor College of Medicine, Houston, TX., Guedes VA; National Institutes of Health, Bethesda, MD., Richard MA; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX., Pugh SL; NRG Oncology Statistics and Data Management Center, Philadelphia PA.; American College of Radiology, Philadelphia PA., Armstrong TS; National Institutes of Health, Bethesda, MD., Scheurer ME; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX.; Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.

Publikováno v: Neuro-oncology [Neuro Oncol] 2024 Nov 16. Date of Electronic Publication: 2024 Nov 16.

NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.

Autor: Batchelor TT; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Won M; Department of Statistics, NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA., Chakravarti A; Department of Radiation Oncology, Wexner Medical Center, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Hadjipanayis CG; Department of Neuro-Oncology, Neurosurgery, University of Pittsburgh Medical Center, Pittsburg, Pennsylvania, USA., Shi W; Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA., Ashby LS; Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA., Stieber VW; Department of Radiation Oncology, Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, USA., Robins HI; Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA., Gray HJ; Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, Washington, USA., Voloschin A; Department of Neuro-Oncology, Orlando Health Cancer Institute, Orlando, Florida, USA., Fiveash JB; Department of Radiation Oncology, University of Alabama at Birmingham Medical Center, Birmingham, Alabama, USA., Robinson CG; Department of Radiation Oncology, Washington University, St. Louis, Missouri, USA., Chamarthy U; Department of Medical Oncology/Hematology, Sparrow HH Cancer Center, Lansing, Michigan, USA., Kwok Y; Department of Radiation Oncology, University of Maryland Medical Systems, Baltimore, Maryland, USA., Cescon TP; Department of Hematology, Reading Hospital, Reading, Pennsylvania, USA., Sharma AK; Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina, USA., Chaudhary R; Department of Hematology Oncology, University of Cincinnati, Cincinnati, Ohio, USA., Polley MY; Department of Statistics, NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.; Department of Statistics, University of Chicago, Chicago, Illinois, USA., Mehta MP; Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA (M.P.M.).

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2023 Oct 11; Vol. 5 (1), pp. vdad116. Date of Electronic Publication: 2023 Oct 11 (Print Publication: 2023).